Literature DB >> 15142878

Platelet surface glutathione reductase-like activity.

David W Essex1, Mengru Li, Richard D Feinman, Anna Miller.   

Abstract

We previously found that reduced glutathione (GSH) or a mixture of GSH/glutathione disulfide (GSSG) potentiated platelet aggregation. We here report that GSSG, when added to platelets alone, also potentiates platelet aggregation. Most of the GSSG was converted to GSH by a flavoprotein-dependent platelet surface mechanism. This provided an appropriate redox potential for platelet activation. The addition of GSSG to platelets generated sulfhydryls in the beta subunit of the alpha(IIb)beta(3) fibrinogen receptor, suggesting a mechanism for facilitation of agonist-induced platelet activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142878     DOI: 10.1182/blood-2004-03-1097

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  A new antithrombotic strategy: inhibition of the C-terminal active site of protein disulfide isomerase.

Authors:  L Wang; D W Essex
Journal:  J Thromb Haemost       Date:  2017-02-28       Impact factor: 5.824

2.  Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease.

Authors:  Gregory N Prado; Jose R Romero; Alicia Rivera
Journal:  FASEB J       Date:  2013-08-02       Impact factor: 5.191

3.  The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.

Authors:  Junsong Zhou; Yi Wu; Lu Wang; Lubica Rauova; Vincent M Hayes; Mortimer Poncz; David W Essex
Journal:  J Clin Invest       Date:  2015-11-03       Impact factor: 14.808

4.  The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses.

Authors:  Zhenzhen Zhao; Yi Wu; Junsong Zhou; Fengwu Chen; Aizhen Yang; David W Essex
Journal:  Blood       Date:  2018-11-13       Impact factor: 25.476

Review 5.  The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System.

Authors:  Oskar Eriksson; Camilla Mohlin; Bo Nilsson; Kristina N Ekdahl
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 6.  Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.

Authors:  Sergio Pandolfi; Salvatore Chirumbolo; Giovanni Ricevuti; Luigi Valdenassi; Geir Bjørklund; Roman Lysiuk; Monica Daniela Doşa; Larysa Lenchyk; Serafino Fazio
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-12-02       Impact factor: 3.688

Review 7.  Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19.

Authors:  Aram Yegiazaryan; Arbi Abnousian; Logan J Alexander; Ali Badaoui; Brandon Flaig; Nisar Sheren; Armin Aghazarian; Dijla Alsaigh; Arman Amin; Akaash Mundra; Anthony Nazaryan; Frederick T Guilford; Vishwanath Venketaraman
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.